Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2014 1
2015 2
2016 2
2017 2
2018 3
2019 1
2020 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Correction to: Steven Deitelzweig et al., Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S, Luo X, Gupta K, Mardekian J, Trocio JN, Curtice T, Lingohr-Smith M, Menges B, Lin J. Deitelzweig S, et al. Curr Med Res Opin. 2018 Jan;34(1):11-12. doi: 10.1080/03007995.2017.1397989. Epub 2017 Nov 2. Curr Med Res Opin. 2018. PMID: 29095647 No abstract available.
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials.
Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Amin A, et al. Among authors: deitelzweig s. J Thromb Thrombolysis. 2014;38(2):150-9. doi: 10.1007/s11239-013-1048-z. J Thromb Thrombolysis. 2014. PMID: 24477787 Review.
Correction: Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID‑19 in the United States: a retrospective cohort study.
Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G. Deitelzweig S, et al. J Thromb Thrombolysis. 2022 Nov;54(4):696. doi: 10.1007/s11239-022-02708-3. Epub 2022 Sep 19. J Thromb Thrombolysis. 2022. PMID: 36121539 Free PMC article. No abstract available.
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study.
Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G. Deitelzweig S, et al. J Thromb Thrombolysis. 2022 May;53(4):766-776. doi: 10.1007/s11239-022-02644-2. Epub 2022 Apr 30. J Thromb Thrombolysis. 2022. PMID: 35489004 Free PMC article.
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.
Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Li X, et al. Among authors: deitelzweig s. PLoS One. 2018 Jan 26;13(1):e0191722. doi: 10.1371/journal.pone.0191722. eCollection 2018. PLoS One. 2018. PMID: 29373602 Free PMC article.
All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants.
Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Hlavacek P, Lingohr-Smith M, Menges B, Lin J. Deitelzweig S, et al. Clin Appl Thromb Hemost. 2018 May;24(4):602-611. doi: 10.1177/1076029617750269. Epub 2018 Jan 24. Clin Appl Thromb Hemost. 2018. PMID: 29363999 Free PMC article.
17 results